Yahoo Finance

Boehringer Ingelheim and Tessellate Bio partner to develop first-in-class precision treatments for people with hard-to-treat cancers

Ingelheim, Germany and Amsterdam, the Netherlands, 23 April 2025 – Boehringer Ingelheim and Tessellate Bio, a precision oncology company with a focus on developing novel synthetic lethality approaches ...
PharmiWeb

Tessellate BIO, Omico and CMRI announce a multi-year collaboration to accelerate discovery of synthetic lethal precision therapies to address ‘ALT’ cancers

Amsterdam, the Netherlands and Sydney, Australia 30 September 2024 - Tessellate BIO, a preclinical stage biotechnology company with a focus on novel Synthetic Lethality approaches, announces a ...
manilatimes

Tessellate BIO Announces Appointment of Lara Boyd as Chief Business Officer

AMSTERDAM and STEVENAGE, United Kingdom, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Tessellate BIO, a preclinical stage biotechnology company with a focus on novel Synthetic Lethality approaches, today ...
markets.financialcontent

Boehringer Ingelheim and Tessellate Bio partner to develop first-in-class precision treatments for people with hard-to-treat cancers

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness. Ingelheim, Germany and Amsterdam, the Netherlands, 23 ...